Investigation of association between vonoprazan concentration and CYP3A activity in upper gastrointestinal disease

Investigation of association between vonoprazan concentration and CYP3A activity in upper gastrointestinal disease - Investigation of association between vonoprazan concentration and CYP3A activity in upper gastrointestinal disease

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000042996

Enrollment

Registered

2021-01-14

Start date

2018-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

upper gastrointestinal tract disease gastroesophageal reflux disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients treated with vonoprazan for upper gastrointestinal disease 2. Patients receiving written informed consent

Exclusion criteria

Exclusion criteria: 1. Patients discontinuing vonoprazan treatment 2. Patients who are judged by physicians as in appropriate for study enrollment

Design outcomes

Primary

Measure	Time frame
Concentration of vonoprazan and its metabolite before dosing on day 4 or later	—

Countries

Japan

Contacts

Public ContactTakafumi Naito

Hamamatsu University School of Medicine Department of Hospital pharmacy

pharmacyham-adm@umin.ac.jp053-435-2763

Outcome results